Providing for consideration of the bill (H.R. 4566) to amend the Dodd-Frank Wall Street Reform and Consumer Protection Act to provide relief to nonbanks from certain stress test requirements under such Act; providing for consideration of the bill (H.R. 5247) to authorize the use of eligible investigational drugs by eligible patients who have been diagnosed with a stage of a disease or condition in which there is reasonable likelihood that death will occur within a matter of months, or with another eligible illness, and for other purposes; and for other purposes.

Cost and committee reports

Official records Congress.gov attaches to H.Res. 787.

• Committee reportCongress.gov lists 1 committee report for this bill: H. Rept. 115-613 ↗.
  Source: Congress.gov, record updated April 7, 2025 ↗

  Evidence

  Field in the Congress.gov record

  committeeReports

  Report API records

  https://api.congress.gov/v3/committee-report/115/HRPT/613

  Congress.gov bill record

  H.Res. 787, 115th Congress

  Congress.gov API record

  https://api.congress.gov/v3/bill/115/hres/787

  Record last updated by Congress.gov

  April 7, 2025

  PORKER copy retrieved

  September 22, 2026

  Stored copy, SHA-256 of the file

  00bc5f07f922dc397408c5c5af27da607e86c57b3c7c672b9fe5ab342222c0c6

  A committee report is the committee’s own explanation of the bill. PORKER lists it and links to it; reading it is up to you.

Congress.gov’s record for this bill does not list a CBO cost estimate (as of April 7, 2025). Not every bill gets one.

From the Congress.gov bill record for H.Res. 787, last updated April 7, 2025. PORKER’s copy was retrieved September 22, 2026 and is refreshed nightly. Open “Evidence” on any line for the record, field and file fingerprint.